Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Thomas

Clinical Nurse Specialist, Adult Health Paducah, KY Clinical Nurse Specialist

NPI 1346355450 CMS profile 10916939

225 Medical Center Dr, Ste 307, Paducah, KY 42003

Open in the dashboard

General payments

$7,363

395 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Thomas of Paducah, KY is reported in the CMS Open Payments database as having received $7,363 across 395 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,024 156
2024 General $2,256 123
2023 General $979 49
2022 General $658 39
2021 General $446 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Thomas
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Jennifer Thomas were reported at $3,024. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Jennifer Thomas Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $446 $133 $48–$445 $132
2022 $658 $163 $57–$526 $149
2023 $979 $173 $64–$597 $160
2024 $2,256 $171 $54–$575 $164
2025 $3,024 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,513 95 payments
  2. Janssen Biotech, Inc. $1,136 49 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,066 49 payments
  4. Phathom Pharmaceuticals, Inc. $637 57 payments
  5. QOL Medical, LLC $395 19 payments
  6. Ardelyx, Inc. $312 12 payments
  7. Braintree Laboratories, Inc. $278 18 payments
  8. Madrigal Pharmaceuticals $274 11 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $247 14 payments
  10. Pfizer Inc. $221 13 payments
  11. Other $1,284 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,363 395 payments
Products named General payments · program years 2021–2025
  1. ENTYVIO $888 41 payments
  2. RINVOQ $768 49 payments
  3. TREMFYA $710 29 payments
  4. STELARA $541 21 payments
  5. VOQUEZNA Gastroenterology $389 37 payments
  6. SKYRIZI Immunology $358 23 payments
  7. IBSRELA $312 12 payments
  8. HUMIRA $306 17 payments
  9. SKYRIZI Immunology $276 15 payments
  10. VOQUEZNA Gastroenterology $248 20 payments
  11. Other $3,772 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,306

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$302,666

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

40.8%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 17 $224,066
Mesalamine Generic 29 $19,908
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 215 $14,522
Linzess Linaclotide Brand 13 $7,668
Mesalamine Er Mesalamine Brand 21 $7,458
Dexlansoprazole Dr Dexlansoprazole Brand 22 $6,364
Colestipol Hcl Generic 51 $3,843
Pantoprazole Sodium Generic 270 $3,366
Esomeprazole Magnesium Generic 92 $3,169
Ursodiol Generic 15 $2,290

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$48,991

Medicare's payments for the services billed

Medicare patients

593

Average age 74

Services billed

744

319 women, 274 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 31%
Ischemic heart disease 28%
Chronic kidney disease 27%
Depression 26%
COPD 24%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $398
$398 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $267
$267 — —
STELARA
  • Janssen Biotech, Inc. $170
$170 — —
Sucraid
  • QOL Medical, LLC $160
$160 — —
RINVOQ
  • AbbVie, Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record